Jason B. Daly is CLO & VP at Amneal Pharmaceuticals, Inc. (AMRX). They have made 5 open-market trades across 1 company since 2024, most recently 2026-08-12.
CIK 0001906486
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AMRX | 35,171 | $674K |
Shares reported on the most recent Form 4, priced at the 2026-08-13 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AMRX | SELL | 2026-08-11 | 2026-08-13 | $17.41 | $3.8M | +4.9% | +0.7% | — |
| AMRX | SELL | 2025-08-12 | 2025-08-13 | $9.05 | $398K | -0.3% | +7.4% | +28.4% |
| AMRX | SELL | 2025-03-05 | 2025-03-07 | $8.80 | $1.6M | +0.3% | -17.1% | -17.6% |
| AMRX | SELL | 2024-11-21 | 2024-11-22 | $8.40 | $115K | +1.5% | -8.4% | -7.4% |
| AMRX | SELL | 2024-11-15 | 2024-11-19 | $8.61 | $752K | +2.3% | -7.5% | -7.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.